ProShares Trust - ProShares S&P 500 Dividend Aristocrats ETF
NOBL
Get informed when a big investor buys or sells
+ FollowMarket Cap$31.66B
Close$
Share Statistics
| Market cap | $31.66 Billion |
|---|---|
| Enterprise Value | $31.48 Billion |
| Dividend Yield | $2.27 (3.14%) |
| Earnings per Share | $- |
| Beta | 0.71 |
| Outstanding Shares | - |
Return
| Return on Equity | -25.93% |
|---|---|
| Return on Assets | -23.92% |
| Return on Invested Capital | -27.36% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2410.83 |
| Enterprise Value to EBIT | -418.83 |
| Enterprise Value to Net Income | -447 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.7872▲ 149.03% |
|---|---|
| Total Calls | 103,400▲ 189.64% |
| Total Puts | 184,800▲ 1643.40% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 47.92%▼ 3.09% |
|---|---|
| Total Invested | $5.19B▼ 1.91% |
| Investors Holding | 820▲ 5.00% |
ESG Score
No data
About BioAge Labs, Inc.
62 employees
CEO: Dr. Kristen Fortney Ph.D. BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets bas...